Cyclerion Therapeutics Inc Dossier - Source-backed chat

Cyclerion Therapeutics Inc

CYCNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.47

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $23.52Price as of 8 Sep 2026

Data confidenceNot applicable

Market Cap $15.7M

Enterprise Value $14.3M

Shares Outstanding 668.8K diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cyclerion Therapeutics is undergoing a complete structural transformation. In April 2026, the company announced a definitive merger agreement with privately held Korsana Biosciences. Upon closing (expected in Q3 2026), the combined company will operate under the name Korsana Biosciences, Inc. and trade under the ticker 'KRSA'. Pre-merger Cyclerion shareholders will retain only a 1.5% equity stake in the combined entity, which is heavily backed by a $380 million private financing syndicate. While Cyclerion's legacy neuropsychiatric asset CYC-126 (for treatment-resistant depression) remains on track for a Phase 2 trial in 2H 2026, the investment thesis is now almost entirely driven by Korsana's preclinical Alzheimer's candidate, KRSA-028, and its THETA brain-shuttle platform. Given the extreme dilution of existing shareholders and the shift in core focus to early-stage neurodegenerative pipelines, a Hold recommendation is advised until the merger closes and clinical execution begins.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$8.00

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The merger faces regulatory or shareholder delays, or Nasdaq listing approval is withheld, jeopardizing the $380 million concurrent financing. If the merger fails, Cyclerion's standalone cash runway remains extremely limited (previously estimated to fund operations only through mid-2026), forcing highly dilutive capital raises or a halt to the CYC-126 Phase 2 clinical program.

Base CaseCentral scenario

The merger with Korsana Biosciences closes successfully in Q3 2026, and the concurrent $380 million private financing is secured. This extends the combined company's cash runway into 2029, fully funding operations through key clinical milestones. CYC-126 initiates its Phase 2 trial in Australia in late 2026, and Korsana's lead asset KRSA-028 enters Phase 1 trials in mid-2027, with initial amyloid plaque clearance data expected by the end of 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Substantial post-merger cash runway funded into 2029 via a $380 million oversubscribed private placement.
Access to Korsana's proprietary THETA platform, designed to shuttle monoclonal antibodies across the blood-brain barrier to treat Alzheimer's disease with improved safety and subcutaneous convenience.
CYC-126 has received positive written regulatory feedback from the FDA, supporting its Phase 2 proof-of-concept study design in treatment-resistant depression.

Key Investment Risks

Severe dilution for existing Cyclerion shareholders, who will collectively own only approximately 1.5% of the combined company at closing.
High execution and clinical development risk, as both CYC-126 and KRSA-028 are early-stage assets with proof-of-concept data not expected until late 2027.
The transaction is subject to numerous closing conditions, including shareholder votes and Nasdaq listing approval.

Thesis Invalidation Triggers

Failure to obtain shareholder approval for the merger, reverse stock split, or redomestication proposals.
Inability to close the concurrent $380 million private financing.
Delays in initiating the CYC-126 Phase 2 trial in Australia in 2H 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.